CMTx Biotech is pursuing new therapeutic uses and formations of clinical stage drug candidates
CMTx Biotech is pursuing new therapeutic uses and formulations of drugs already approved for human use
Host-directed therapeutics (HDT's) are a promising class of treatments that target the hyper-inflammatory and dysregulated immune response to infection, insult, or injury.
HDTs have the advantage of being threat agnostic, and can serve as an adjunctive treatment to current standard of care.
Our lead drug candidate, incyclinide, has completed IND-enabling studies and has been tested safely in humans in a variety other indications.
CMTx R2 is an inhibitor of the Suppressor of T-cell Signaling (STS) proteins approved for human use internationally.
CMTx is advancing this candidate for host-directed treatment of infectious diseases.
Our management team is composed of a seasoned group of scientists, business managers, technology commercialization and licensing experts.
Together we have past experience developing, manufacturing, and commercializing a variety of products.

Former VP of Research,
CollaGenex Pharmaceuticals

Director, Translational Critical Care Laboratory, SUNY Upstate Medical University

Associate Professor,
Division of Pediatric Surgery
University of Arkansas

Professor, Nucleotide Metabolism & Drug Discover
The Hormel Institute
University of Minnesota
Please contact us
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.